Pharmaco-Invasive Strategy With Half-Dose Tenecteplase in Patients With STEMI: Prespecified Pooled Analysis of Patients Aged ≥75 Years in STREAM-1 and 2
Circulation: Cardiovascular Interventions · 2024
DOI: 10.1161/circinterventions.124.014251 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Circulation: Cardiovascular Interventions, 2024. Verfasst von Kevin R Bainey und 20 weiteren Autor:innen. Beteiligte Einrichtung: Canadian VIGOUR Centre (K.R.B., R.C.W., Y.Z., T.T., E.L., C.M.W., P.W.A.), University of Alberta, Edmonton, Canada. Hauptthemen laut MEDLINE: Fibrinolytic Agents, Percutaneous Coronary Intervention, ST Elevation Myocardial Infarction, Tenecteplase. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: In STREAM-1 (Strategic Reperfusion Early After Myocardial Infarction), excess intracranial hemorrhage occurred in patients aged ≥75 years receiving full-dose tenecteplase as part of a pharmaco-invasive strategy, whereas no further intracranial hemorrhage occurred after halving the tenecteplase dose. In STREAM-2 (Second Strategic Reperfusion Early After Myocardial Infarction), half-dose tenecteplase was an effective and safe pharmaco-invasive strategy in older patients with ST-segment–elevation myocardial infarction presenting within
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Canadian VIGOUR Centre (K.R.B., R.C.W., Y.Z., T.T., E.L., C.M.W., P.W.A.), University of Alberta, Edmonton, Canada.
- Mazankowski Alberta Heart Institute (K.R.B., R.C.W.), University of Alberta, Edmonton, Canada.
- Coronary Care Unit, National Institute of Cardiology, Mexico City, Mexico (A.A.-M.).
- Department of Cardiology, University Clinical Center of Serbia, University of Belgrade, Serbia (A.D.R.).
- Pirogov Russian National Research Medical University and City Clinical Hospital, Moscow (O.V.A.).
- Centre Hospitalier de Versailles, Service d'aide Médicale Urgente 78 and Mobile Intensive Care Unit, Le Chesnay, France (Y.L.).
ORCID-Profile: Kevin R Bainey, Yinggan Zheng, Alexandra Arias-Mendoza, Arsen D Ristic, Oleg V Averkov, Yves Lambert, José F Kerr Saraiva, Pablo Sepulveda, Fernando Rosell-Ortiz, John K French, Tracy Temple, Eric Ly, Kris Bogaerts, Peter R Sinnaeve, Thierry Danays, Cynthia M Westerhout, Frans Van de Werf, Paul W Armstrong
Zitieren
APA
Bainey, K. R., Welsh, R. C., Zheng, Y., Arias-Mendoza, A., Ristic, A. D., Averkov, O. V., Lambert, Y., Kerr Saraiva, J. F., Sepulveda, P., Rosell-Ortiz, F., French, J. K., Musić, L. B., Temple, T., Ly, E., Bogaerts, K., Sinnaeve, P. R., Danays, T., Westerhout, C. M., Van de Werf, F., …, & STREAM-2 Investigators (2024). Pharmaco-Invasive Strategy With Half-Dose Tenecteplase in Patients With STEMI: Prespecified Pooled Analysis of Patients Aged ≥75 Years in STREAM-1 and 2. Circulation: Cardiovascular Interventions. https://doi.org/10.1161/circinterventions.124.014251
Vancouver
Bainey KR, Welsh RC, Zheng Y, Arias-Mendoza A, Ristic AD, Averkov OV, et al. Pharmaco-Invasive Strategy With Half-Dose Tenecteplase in Patients With STEMI: Prespecified Pooled Analysis of Patients Aged ≥75 Years in STREAM-1 and 2. Circulation: Cardiovascular Interventions. 2024. doi:10.1161/circinterventions.124.014251
BibTeX
@article{Bainey2024,
author = {Bainey, Kevin R and Welsh, Robert C and Zheng, Yinggan and Arias-Mendoza, Alexandra and Ristic, Arsen D and Averkov, Oleg V and Lambert, Yves and Kerr Saraiva, José F and Sepulveda, Pablo and Rosell-Ortiz, Fernando and French, John K and Musić, Ljilja B and Temple, Tracy and Ly, Eric and Bogaerts, Kris and Sinnaeve, Peter R and Danays, Thierry and Westerhout, Cynthia M and Van de Werf, Frans and Armstrong, Paul W and STREAM-2 Investigators, STREAM-2 Investigators},
title = {Pharmaco-Invasive Strategy With Half-Dose Tenecteplase in Patients With STEMI: Prespecified Pooled Analysis of Patients Aged ≥75 Years in STREAM-1 and 2},
journal = {Circulation: Cardiovascular Interventions},
year = {2024},
doi = {10.1161/circinterventions.124.014251}
}
EUVIMED